Accession Number: | 0001209191-19-029182 |
Date: | 2019-05-10 |
Issuer: | FLEXION THERAPEUTICS INC (FLXN) |
Original Submission Date: |
CLAYMAN MICHAEL D.
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON, MA 01803
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2019-05-10 | P | 4,012 | a | $12.48 | 74,868 | direct | ||
COMMON STOCK | 2019-05-10 | 0 | $0.00 | 314,066 | indirect | ||||
COMMON STOCK | 2019-05-10 | 0 | $0.00 | 24,600 | indirect | ||||
COMMON STOCK | 2019-05-10 | 0 | $0.00 | 388,683 | indirect | f2 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the weighted average purchase price for the transaction reported was $12.47940, and the range of prices were between $12.470 and $12.481. upon request by the sec staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. |
f2 | shares held by versant development fund iii, llc. the reporting person is a manager and minority member of versant development fund iii, llc. the reporting person disclaims any beneficial ownership of the shares held by versant development fund iii, llc except to the extent of his pecuniary interest in these shares. |